Evidence map›Paper›PMID 41589129›Full record

ArticleJournal of clinical biochemistry and nutrition2026

Lipoprotein(a): structural basis, bidirectional risk, and therapeutic frontiers.

Zeyu Xu, Yi Fang, Yong Peng, Chunhua Zhang, Chunhua Zheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical biochemistry and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zeyu XuThe Third Affiliated Hospital of Nanchang University, 128 Xiangshan North Road, Donghu District, Nanchang City, Jiangxi Province, 330008, China.
Yi FangThe Third Affiliated Hospital of Nanchang University, 128 Xiangshan North Road, Donghu District, Nanchang City, Jiangxi Province, 330008, China.
Yong PengThe Third Affiliated Hospital of Nanchang University, 128 Xiangshan North Road, Donghu District, Nanchang City, Jiangxi Province, 330008, China.
Chunhua ZhangThe Third Affiliated Hospital of Nanchang University, 128 Xiangshan North Road, Donghu District, Nanchang City, Jiangxi Province, 330008, China.
Chunhua ZhengThe Third Affiliated Hospital of Nanchang University, 128 Xiangshan North Road, Donghu District, Nanchang City, Jiangxi Province, 330008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite substantial progress in the management of cardiovascular disease (CVD), lipoprotein(a) [Lp(a)] persists as a genetically determined risk factor that remains insufficiently explored. Both extremely high and low levels of Lp(a) are linked to adverse outcomes. Current diagnostic assays for Lp(a) lack standardization, and conventional lipid-lowering therapies exert minimal effects on its levels, resulting in limited treatment options specifically targeting Lp(a). To address these gaps, we conducted a comprehensive molecular and clinical review of Lp(a), examining its unique structure, genetic determinants, metabolic pathways, and the factors influencing its plasma concentration. Furthermore, we discuss emerging therapeutic strategies aimed at targeting Lp(a).

Indexed as

cardiovascular diseaselipoprotein(a); Lp(a)mortality risktreatment

Identifiers

PMID41589129
PMCPMC12832145

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.